Dec 17, 2021 / 12:45PM GMT
Operator
Good day, and welcome to the Genfit's Corporate Update Conference Call. At this time, I would like to turn the conference over to Ms. Stefanie Magner. Please go ahead, ma'am.
Stefanie Magner - Genfit SA - Chief Compliance Officer & VP of International Legal Affairs
Thank you, and good afternoon, everyone, and thank you for joining us on this conference call, organized to follow-up the 2 press releases we published this morning. The first press release announced the global long-term strategic partnership with Ipsen, beginning with PBC. The second one announced an in-licensing agreement with Genoscience Pharma for an early-stage compound that will be developed as part of our costatic disease franchise. These press releases can be accessed via our website at ir.genfit.com.
During our call, we will be making forward-looking statements as defined under the U.S. Private Securities Litigation Reform Act of 1995 with respect to Genfit, including relating to timing of top line results in the ELATIVE Phase III study, the commercial potential of elafibranor as
Genfit SA Corporate Call Transcript
Dec 17, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers